Motif Bio PLC (MTFB) Quote

Don’t know it yet ? Not sure how it’s going to go at all! Voluntarily delisted company ... will see.

What is the New stock symbol now for MTFB --- check your portfolio to find it? TIA!

Yes I still own. Missed my opportunity to sell. I guess nothing happens til March ??

Do you still own any shares now? If the answer is "yes" then you should know what is the New stock symbol now? Perhaps all the common shares were already canceled?

It’s a mystery for now!

Attention All: Where the NASDAQ stock MTFB went now? Cancelled? Or symbol change? TIA!

Some serious after hours trading ? So curious as to what will happen with this ?

11th Nov 2019 09:52
(Alliance News) - Motif Bio PLC said Monday it agreed to settle all obligations with its former clinical research organisation without requiring any further payments.

For the six months ended June, Motif had recognised an additional USD2.4 million expense to settle this dispute. This recognition will be reversed following the agreement.

Shares in Motif Bio were 8.3% lower at 0.43 pence in London on Monday.

In October, Motif Bio announced a major restructure which would see its sell its main listeria-fighting drug iclaprim. This followed US regulators requiring iclaprim to pass further hurdles to secure new drug application status.

24th Oct 2019 16:05
(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with 'iclaprim', to improve safety and efficacy administered by a novel enhanced aerosol technology, it announced on Thursday.
The AIM-traded firm said the aerosol technology allowed the delivery of antibiotics "painlessly and rapidly" into skin and soft tissue, with low-pressure and focused delivery.

It said the research was being funded through a grant from the US Department of Defense - Congressionally Directed Military Infectious Diseases Research Program, to evaluate the potential of using such a drug-device combination for wound care and to prevent and treat wound infections on the battlefield.

"When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible," said Motif Bio chief medical officer David Huang.

"The data generated from [research lead] Dr Zurawski's research will be important in understanding whether iclaprim delivered locally could play a role in treating battlefield wound infections."

Nice !!

14 November 2019

Motif Bio plc

Result of General Meeting

http://ir.motifbio.com/static-files/c6ba285f-e43f-4e95-beb9-f4b5837cf45d

I knew I liked what I saw...that’s why I bought when I did!
So Happy!!

in

https://newsfilter.io/articles/sc-13da-form---amend-general-statement-of-acquisition-of-beneficial-ownership---motif-bio-plc-000167-f70c5b3bd2a8a7950a7327863238fedd

MTFB Will Go To 5 Cents And Then Zero. You may want to read this latest 6 k very carefully. There are lots of if and buts to even make any of this shit show survive.
Short sellers will crush what is left of this nothing. Hercules owns them period!
They clearly stated the phase three will take millions of dollars and they are not capable of doing it. They are trying to get something for it just to pay off Hercules! Its a dumpster fire!
They clearly stated the company is considering delisting from the Nasdaq!
And then they talk about a reverse take over. Wall Street hates reverse take overs. OTC idiots are the ones who like reverse take overs.
Hell I may even short this and I normally only short stocks above 1.75!

$MTFB... may not be quick.. but they are transparent
--
and interesting FDA said they need phase three testing ... might
take some time and money ...
--
Then they get a grant from the US MILITARY for testing ...
--
Hmm... the Military is always the start of something that eventually
gets into the Public side... and they do have deep pockets.
===
TIME will tell.

$MFTB
--
should remain on a watch list... and about the filing 6K , 10/25,
--
(ie) .. they have seventeen plus 6k's , so that was nothing new,
the real deal was the big blow back in FEB ...
--
They are restructuring ... is all in that phase.
--
One needs to look at how low will it go as it was once $10.00 and
moving nicely ... so TIME will tell.
--
Now if they were doing NOTHING .. then Nothing would happen,
--
they control alot internally .. and are pretty transparent about what they are doing.. they do not want to lose their trading status obviously.

Heads Up 6k Was Filed Oct 25 Here is a few details but not all.
Proxy meeting Nov 14 2019
FDA meeting of Sept 19 2019 results. MTFB figure would take at least 2 years and millions of dollars to finish Phase 3
Current cash they have basically null.

2 Loan payments postponed by lender Hercules till end of Oct.

Vote on orderly sale or wind down of MOTIF Inc with the result of the company to become a cash shell.
And basically would have to pay off Hercules. And they own it.
Few other things of interest you may want to read about also in report.

Had this on my watch list for awhile glad I stayed on the sidelines.
Anyways I see no reason to keep on watch list myself any longer.

I like what I see

Watch this ...
--
First the Military .. then into the Public Medical applications
--
Motif Bio Shares Jump After Signing U.S. Army-Funded Project
3:50 AM ET 10/24/19 | Dow Jones


By Sabela Ojea

Shares in Motif Bio PLC (MTFB.LN) rose 27% on Thursday after the company said that it has signed a U.S. Army-funded research project to evaluate Iclaprim, which would be used to prevent and treat wound infections on the battlefield.

The clinical-stage biopharmaceutical company said it has signed the contract with the Walter Reed Army Institute of Research through a grant from the U.S. Department of Defense.

The London-listed company added aerosol technology allows delivery of antibiotics painlessly and rapidly into skin and soft tissue with low-pressure and focused delivery.

"When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible," Chief Medical Officer David Huang said.

Shares at 0745 GMT were up 0.17 pence at 0.80 pence.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

> Dow Jones Newswires

* * $MTFB Video Chart 10-24-2019 * *

Link to Video - click here to watch the technical chart video

* * $MTFB Video Chart 09-30-2019 * *

Link to Video - click here to watch the technical chart video

Nice 50% drop today.

Yep

Just keep... Bleeding and Bleeding and Bleedingggggg

Glad to see you here kind sir. MTfb

Bring on the news as well. Get the party started

Need more money for tomorrow and we ride height

MTfb bring it good glad to be in

Wonder what they said during the conference today. Anyone?

D-day

Any thoughts on this FDA meeting?

Is there a broker that carries options for this one?

$MTFB - Bottom-Watch Play

will this go up today or we crash to 1

* * $MTFB Video Chart 03-20-2019 * *

Link to Video - click here to watch the technical chart video

Hopefully Get some tomorrow

Good observation....let's see if we have a filing after the bell. Looks like a bit of company dilution INTO THE NEWS.

Let's see what happens here at $2.50. I think we have another big run ahead in the next week based on the news and that the drop from $4.24 the HOD and $3.25 was on low volume. Look at the AM daily chart and huge volume in the $3.25 to $4.25 range. Then it dwindles as the PPS drops mostly by day traders and stop losses.

Going up.

got in at 2.62 and will see what the next hour brings. It's trader action that dictates the price these days. When day traders cash in eod, who knows?

LOVE IT!! The Company also has plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication. A Phase 2 trial in patients with HABP has been successfully completed and a Phase 3 trial is being planned. Additionally, iclaprim has been granted orphan drug designation by the FDA for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis and is in preclinical development for this indication. Iclaprim has received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track status for the ABSSSI indication. If approved for the ABSSSI indication as a New Chemical Entity, iclaprim will be eligible for 10 years of market exclusivity in the U.S. from the date of first approval, under the Generating Antibiotic Incentives Now Act (the GAIN Act). In Europe, 10 years of market exclusivity is anticipated. Motif is also building a patent estate to provide additional protection for iclaprim and has two U.S. method of use patents issued that will expire in 2037.

slow grind back down

Ive made several green trades

waiting to see what happens next

MTFB

$MTFB boom. Mentioned sub $2 on Twitter

$3.28 weeeeeeeeeee! BOOM!

$3 added...